263 related articles for article (PubMed ID: 14629980)
1. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
Gund TM; Floyd J; Jung D
J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
[TBL] [Abstract][Full Text] [Related]
2. Receptor site topographies for phencyclidine-like and sigma drugs: predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses.
Manallack DT; Wong MG; Costa M; Andrews PR; Beart PM
Mol Pharmacol; 1988 Dec; 34(6):863-79. PubMed ID: 2849051
[TBL] [Abstract][Full Text] [Related]
3. 5D-QSAR for spirocyclic sigma1 receptor ligands by Quasar receptor surface modeling.
Oberdorf C; Schmidt TJ; Wünsch B
Eur J Med Chem; 2010 Jul; 45(7):3116-24. PubMed ID: 20427100
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
Peng T; Pei J; Zhou J
J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
Zampieri D; Mamolo MG; Laurini E; Florio C; Zanette C; Fermeglia M; Posocco P; Paneni MS; Pricl S; Vio L
J Med Chem; 2009 Sep; 52(17):5380-93. PubMed ID: 19673530
[TBL] [Abstract][Full Text] [Related]
6. Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling.
Banister SD; Moussa IA; Jordan MJ; Coster MJ; Kassiou M
Bioorg Med Chem Lett; 2010 Jan; 20(1):145-8. PubMed ID: 19954972
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-affinity relationships of novel spirocyclic sigma receptor ligands with furopyrazole structure.
Schläger T; Schepmann D; Würthwein EU; Wünsch B
Bioorg Med Chem; 2008 Mar; 16(6):2992-3001. PubMed ID: 18221879
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
9. A comparative molecular field analysis (CoMFA) study using semiempirical, density functional, ab initio methods and pharmacophore derivation using DISCOtech on sigma 1 ligands.
Jung D; Floyd J; Gund TM
J Comput Chem; 2004 Aug; 25(11):1385-99. PubMed ID: 15185333
[TBL] [Abstract][Full Text] [Related]
10. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents.
Prasad V; Birzin ET; McVaugh CT; Van Rijn RD; Rohrer SP; Chicchi G; Underwood DJ; Thornton ER; Smith AB; Hirschmann R
J Med Chem; 2003 May; 46(10):1858-69. PubMed ID: 12723949
[TBL] [Abstract][Full Text] [Related]
11. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor.
Kahnberg P; Howard MH; Liljefors T; Nielsen M; Nielsen EØ; Sterner O; Pettersson I
J Mol Graph Model; 2004 Dec; 23(3):253-61. PubMed ID: 15530821
[TBL] [Abstract][Full Text] [Related]
12. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.
Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H
J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357
[TBL] [Abstract][Full Text] [Related]
13. Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
Laggner C; Schieferer C; Fiechtner B; Poles G; Hoffmann RD; Glossmann H; Langer T; Moebius FF
J Med Chem; 2005 Jul; 48(15):4754-64. PubMed ID: 16033255
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
Jasper A; Schepmann D; Lehmkuhl K; Vela JM; Buschmann H; Holenz J; Wünsch B
Eur J Med Chem; 2009 Nov; 44(11):4306-14. PubMed ID: 19709783
[TBL] [Abstract][Full Text] [Related]
15. Another brick in the wall. Validation of the σ1 receptor 3D model by computer-assisted design, synthesis, and activity of new σ1 ligands.
Laurini E; Marson D; Dal Col V; Fermeglia M; Mamolo MG; Zampieri D; Vio L; Pricl S
Mol Pharm; 2012 Nov; 9(11):3107-26. PubMed ID: 23020867
[TBL] [Abstract][Full Text] [Related]
16. Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.
Meyer C; Schepmann D; Yanagisawa S; Yamaguchi J; Dal Col V; Laurini E; Itami K; Pricl S; Wünsch B
J Med Chem; 2012 Sep; 55(18):8047-65. PubMed ID: 22913577
[TBL] [Abstract][Full Text] [Related]
17. Modeling the benzodiazepine receptor binding site by the general three-dimensional structure-directed quantitative structure-activity relationship method REMOTEDISC.
Ghose AK; Crippen GM
Mol Pharmacol; 1990 May; 37(5):725-34. PubMed ID: 2160062
[TBL] [Abstract][Full Text] [Related]
18. Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line.
Ganapathy ME; Prasad PD; Huang W; Seth P; Leibach FH; Ganapathy V
J Pharmacol Exp Ther; 1999 Apr; 289(1):251-60. PubMed ID: 10087012
[TBL] [Abstract][Full Text] [Related]
19. Modeling and molecular dynamics of glutamine transaminase K/cysteine conjugate beta-lyase.
Venhorst J; ter Laak AM; Meijer M; van de Wetering I; Commandeur JN; Rooseboom M; Vermeulen NP
J Mol Graph Model; 2003 Sep; 22(1):55-70. PubMed ID: 12798391
[TBL] [Abstract][Full Text] [Related]
20. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
